A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

Clinical trial NCT02631876 · COMPLETED

Trial details

NCT number: NCT02631876
Sponsor: ImmunoGen, Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Epithelial Ovarian Cancer Primary Peritoneal Carcinoma Fallopian Tube Cancer Ovarian Cancer

Start date: 2016-03-02
Primary completion: 2019-01-01
Enrollment: 366

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.